Shares in Moderna have nearly doubled in value on news that an experimental mRNA-based vaccine it developed together with Merck succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients.
Merck stock jumped around 10%, putting it on track for a record close.
The success paves the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.